Full Rating Report
Key Rating Drivers
India Ratings & Research (Ind-Ra) assigned Cipla Limited’s (Cipla)
INR10,000m commercial paper/short-term debt programme a Short-Term Rating of ‘IND A1+’
on 29 April 2013. The rating reflects Cipla’s low leverage (adjusted debt net of cash/EBITDAR)
of below 1.5x over FY09-FY12 (year end March) providing it headroom to take on additional
debt. Despite investments in capex, free cash flows (FCF) were positive and debt was minimal
over the same period. Ind-Ra expects growth in EBITDA, coupled with limited capex spends
and no major deterioration in working capital cycle, to result in liquidity remaining comfortable.
Robust Growth Prospects:
The rating also factors Cipla’s growth in revenue and profitability
in FY13 led by a favourable demand for low-cost generics and its readily available regulatory
approved large manufacturing facilities. For FY13, Cipla’s revenue grew 18% yoy, led by
growth in export revenue of 20% to INR44bn and domestic revenue growth of 15% yoy to
INR37bn. Export growth was supported by the overall growth in most of the markets coupled
with one-time benefits from the drug Escitalopram and rupee depreciation. One-time benefits
also positively impacted EBITDAR margins which stood at 27% versus 24% in the prior period.
Leading Domestic Formulations Player:
Cipla is one of the top players in the Indian
formulation market with a field force of about 8,000 representatives and strong penetration in
the semi-urban market. With a rise in disposable income, growing investments in healthcare
and continuous launch of products, domestic revenue will continue grow over the medium term.
However, growth could see moderation on account of the impact of the new drug pricing policy.
Growth in Exports:
Cipla’s export revenue in the past has largely relied on a partnership
based model; wherein it would sell generics to foreign partners. However, the company is
looking at building its own front-end network in select geographies. In FY13, the company
announced the acquisition of Cipla Medpro South Africa Ltd. for USD512m. The deal, which
has received shareholder approval and is pending regulatory approval, will provide Cipla with
its own front-end in the South African market that contributes significantly to its export revenue.
The company is building its own product pipeline in the US market. As on date, it has a total of
five ANDA (abbreviated new drug application) filings with the USFDA (US Food and Drug
Administration). It is looking at increasing its filings year on year, the benefits of which are likely
Any unexpected and significant deterioration in liquidity led by a decline in EBITDAR
and/or higher-than-expected cash outflow on account of acquisitions/capex could lead to a
Liquidity and Debt Structure
Cipla will fund the USD512m acquisition’s major portion via internal
As on FYE12, Cipla’s total adjusted debt stood at INR16.8m, 98% of which was in the
form of a contingent liability. Cipla has some pending legal cases of alleged overcharging with
respect to a certain drugs under Drug Price Control Order. The total amount of demand notices
Established in 1935, Cipla is a global pharmaceutical company with a strong presence in the
domestic formulation market. The company has a wide product portfolio with over 2,000
products covering 65 therapeutic segments and over 40 dosage forms. The company has 34
manufacturing facilities that have been approved by various regulatory authorities and exports
to several markets including the US, Europe, South Africa, Australia and the Middle East.
Shareholder Pattern as on 31 March 2013
Cipla is actively looking at a shift in its export strategy. So far, Cipla’s exports have largely relied on a partnership model that supplies low-cost generic drugs to its foreign partners.
However, going forward, the company is looking at actively building a front-end presence in
In terms of capital expenditure, the company is not looking at creating any additional significant
capacities in the medium term. The existing capacities are yet to be fully utilised and would be
sufficient for growth over the medium term. However, acquisitions, given its strategy to set up a
In November 2012, Cipla offered to buy 51% of CiplaMedpro at 8.55 South African Rands
(Rand) a share. In February 2013, Cipla raised it to 10 Rands a share (total offer price
USD512m) to buy 100% of CiplaMedpro. The deal would allow Cipla to have its own front-end
in the African market that contributes 40% to its export revenues. This is a concrete step and a significant shift in Cipla’s export strategy.
In addition to the African market, Cipla is also looking at an active front end presence in the US
markets, benefits of which would accrue over a long term. The company has started to file
abbreviated new drug applications in its own name as opposed to its usual practice of filing applications in its partners’ name due to the partnership agreements. The company has five filings of its own and is targeting to file a minimum of 10-15 applications annually. Given the
high competition in the US market, Cipla is planning to launch niche and difficult to manufacture
products as opposed to me-too products. The company also has a basket of inhalation
(respiratory) products, pending approval.
In India, wherein the company is a market leader, it is focusing on penetrating in semi-urban
cities, increasing institutional selling given the rise in private hospitals and is looking at
launching products in high growth segments such as central nervous system and Oncology.
Over FY09-FY12, Cipla’s revenue grew at a CAGR of 12% to INR70bn. However, during FY10,
Cipla reported a lower revenue growth due to the non-availability of imported raw materials,
lower tender business and un-favorable currency movements. Post FY10, growth has been
modest driven by new products in the domestic market and growth in export revenues.
Coupled with revenue growth, EBITDA, during the past three years, grew by 19%. Margins
improved in FY10 due to lower low margin tender business, reduction in material costs and other expenses. In FY11, Cipla’s margins were impacted by low fixed cost absorption of its SEZ which commenced operations in April 2010. Margins were also impacted by the absence
of operating income i.e. technical fees, export incentives and processing fees (FY10: INR2.6bn,
FY09: INR2.7bn). In FY12, margin improvement was guided by the benefit of certain
rationalisation measures undertaken in FY11, measures undertaken include to cut off small business, rationalization of Cipla’s antiretroviral drug portfolio, etc.
Over FY09-FY12, capex worth INR25bn was incurred mainly to set up manufacturing
capacities for formulations, active pharmaceutical ingredients and R&D facilities. The company
has also undertaken certain small but targeted acquisitions. High margin of above 20%,
coupled with a qualified institutional proceeds issue (INR6.7bn) in FY10 has been used to fund the company’s capex spends and investments. High margin has also resulted in healthy cash flow generation, despite significant investments. Thus, the company has no long-term debt on
its books. Debt, if any, is mostly short-term, undertaken for working capital requirements.
Over FY09-FY12, Cipla’s working capital cycle has lengthened consistently. This is mainly due
to its high inventory days. Given its large product portfolio and in-house manufacturing of
certain raw materials, the company has to maintain a certain level of inventory. For debtors, Cipla’s receivable cycle has seen a yoy improvement. For its domestic business, the debtor period is 21-30 days, whereas for exports it is 90 days.
Despite a lengthy gross working capital cycle and a reduction in credit period, Cipla’s liquidity is comfortable as reflected in consistent positive cash from operations and minimal utilisation of
working capital limits (INR682m within consortium and INR20bn outside consortium). Liquidity
is also supported by minimal interest outgo and no major debt repayments. As on FYE12, the company’s cash balance, which includes liquid mutual fund investments, was INR10bn.
Summary income statement
Operating EBITDA (before income from associates)
Summary balance sheet
Summary cash flow statement
Total non-operating/non-recurring cash flow
Total adjusted net debt/operating EBITDAR
Total debt with equity credit/operating EBITDA
The ratings above were solicited by, or o
n behalf of, the issuer, and therefore, India
Ratings has been compensated for the provision of the ratings.
Copyright 2013 by Fitch, Inc., Fitch Ratings Ltd. and its subsidiaries. One State Street Plaza, NY, NY 10004.Telephone: 1-800-753-4824, (212) 908-0500. Fax: (212) 480-4435. Reproduction or retransmission in whole or in part is prohibited except by permission. All rights reserved. In issuing and maintaining its ratings, India Ratings & Research (India Ratings) relies on factual information it receives from issuers and underwriters and from other sources India Ratings believes to be credible. India Ratings conducts a reasonable investigation of the factual information relied upon by it in accordance with its ratings methodology, and obtains reasonable verification of that information from independent sources, to the extent such sources are available for a given security or in a given jurisdiction. The manner of India Ratings factual investigation and the scope of the third-party verification it obtains will vary depending on the nature of the rated security and its issuer, the requirements and practices in the jurisdiction in which the rated security is offered and sold and/or the issuer is located, the availability and nature of relevant public information, access to the management of the issuer and its advisers, the availability of pre-existing third-party verifications such as audit reports, agreed-upon procedures letters, appraisals, actuarial reports, engineering reports, legal opinions and other reports provided by third parties, the availability of independent and competent third-party verification sources with respect to the particular security or in the particular jurisdiction of the issuer, and a variety of other factors. Users of India Ratings’ ratings should understand that neither an enhanced factual investigation nor any third-party verification can ensure that all of the information India Ratings relies on in connection with a rating will be accurate and complete. Ultimately, the issuer and its advisers are responsible for the accur acy of the information they provide to India Ratings and to the market in offering documents and other reports. In issuing its ratings India Ratings must rely on the work of experts, including independent auditors with respect to financial statements and attorneys with respect to legal and tax matters. Further, ratings are inherently forward-looking and embody assumptions and predictions about future events that by their nature cannot be verified as facts. As a result, despite any verification of current facts, ratings can be affected by future events or conditions that were not anticipated at the time a rating was issued or affirmed.
The information in this report is provided "as is" without any representation or warranty of any kind. A rating provided by India Ratings is an opinion as to the creditworthiness of a security. This opinion is based on established criteria and methodologies that India Ratings is continuously evaluating and updating. Therefore, ratings are the collective work product of India Ratings and no individual, or group of individuals, is solely responsible for a rating. The rating does not address the risk of loss due to risks other than credit risk, unless such risk is specifically mentioned. India Ratings is not engaged in the offer or sale of any security. All India Ratings reports have shared authorship. Individuals identified in a India ratings report were involved in, but are not solely responsible for, the opinions stated th erein. The individuals are named for contact purposes only. A report providing a rating by India Ratings is neither a prospectus nor a substitute for the information assembled, verified and presented to investors by the issuer and its agents in connection with the sale of the securities. Ra tings may be changed or withdrawn at any time for any reason in the sole discretion of India Ratings. India Ratings does not provide investment advice of any sort. Ratings are not a recommendation to buy, sell, or hold any security. Ratings do not comment on the adequacy of market price, the suitability of any security for a particular investor, or the tax-exempt nature or taxability of payments made in respect to any security. India Ratings receives fees from issuers, insurers, guarantors, other obligors, and underwriters for rating securities. The assignment, publication, or dissemination of a rating by India Ratings shall not constitute a consent by India Ratings to use its name as an expert in connection with any registration statement filed under the United States securities laws, the Financial Services and Markets Act of 2000 of the United Kingdom, or the securities laws of any particular jurisdiction including India. Due to the relative efficiency of electronic publishing and distribution, India Ratings research may be available to electronic subscribers up to three days earlier than to print subscribers.
ACUPUNCTURE AND DEPRESSION About depression Depression is a common mental health problem that affects people of all genders, ages, and backgrounds. About two thirds of adults will at some time experience depression severe enough to interfere with their normal activities (Mintel/YouGov, 2006, Stewart et al, 2004). Women are twice as likely as men to become depressed (Stewart et al, 2004) par
SAFETY DATA SHEETaccording to Regulation (EC) No 1907/2006 (REACH) Art. 2280, INSEKT-EX 1. Identification of the substance/mixture and of the company/undertaking Product identifier Identification / trade name: REACH registration number: Relevant identified uses of the substance or mixture and uses advised against Use of the substance / mixture: Details of the supplier of th